Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Completed · Not applicable · Has a placebo group

Conditions studied: Nausea, Vomiting

In brief

The purpose of this study is to compare the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for post-operative nausea and vomiting (PONV) treated with oral aprepitant with or without transdermal scopolamine preoperatively.

Key facts

Study ID

NCT00717054

Run by

Drexel University

People needed

115

Starts

2008-02-01

Expected to finish

2010-03-01

Last updated by the study team

2014-05-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Between 18 and 65 years of age
• American Society of Anesthesiology (ASA) physical status 1-3
• If on oral contraceptive, must be willing to use back up method for 1 month
• Must have 2 risk factors for PONV

You may not qualify if…

• History of vomiting due to middle ear infection, nervous system disorder, or other condition
• Procedure less than 1 hour
• Pregnant or breast feeding
• Antiemetic medication in previous 24 hours
• Narrow-angle glaucoma
• Allergic to belladonna alkaloids
• Hypersensitive to barbiturates
• Prostate hypertrophy
• Severe hepatic disease
• On chemotherapy taking aprepitant
• Fever
• Sepsis
• Taking any of the following medications: Orap, Seldane, Hismanal, Propulsid, Phenytoin, Phenothiazines, Tricyclic antidepressants, Meperidine, Tolbutamide, Aluminum and Magnesium containing Antacids, Anti-cholinergics, Coumadin

Where it is running

• Hahnemann University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.